Aman Bhandari
Aman Bhandari leads the corporate data science/AI function at Vertex Pharmaceuticals. This division integrates and scales advanced analytics and AI (e.g. NLP, machine learning, generative AI/LLMs) across disease and business areas including clinical, commercial, manufacturing and HR. Collaborating directly with executive management, our privacy office and IT, he has developed enterprise capabilities and a model for using AI to drive impact
Prior to joining Vertex in 2017, he held roles at Merck, Genentech, the White House, and the Centers for Medicare and Medicaid Services. In these roles he created the first formal data science team at Merck and while at the White House paved the wave for the first Chief Data Officers across the U.S. Government. Aman earned my PhD in health services research and a master's in epidemiology, with a focus on using large scale data to better understand healthcare. He have been an advisor to data/tech initiatives for the World Bank, USAID, Harvard, Cornell, Ashoka Foundation, Knight News Foundation, Boston Children's Hospital and others.
Session
Informed Consent Forms (ICFs) are critical documents in clinical trials. They are the first, and often most crucial, touchpoint between a patient and a clinical trial study. Yet the process of developing them is laborious, high-stakes, and heavily regulated. Each form must be tailored to jurisdictional requirements and local ethics boards, reviewed by cross-functional teams, and written in plain language that patients can understand. Producing them at scale across countries and disease areas demands manual effort and creates major operational bottlenecks. We used a combination of traditional AI and large language models to autodraft the ICF across clinical trial types, across countries and across disease areas at scale. The build, test, iteration and deployment offers both technical and non technical lessons learned for generative AI applications for complex documents at scale and for meaningful impact.